#USA #Fremont #Alzheimer's Disease #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Launches Revolutionary NULISAqpcr™ AD 5-plex Assay

Alamar Biosciences, Inc., a pioneer in the field of precision proteomics, has announced the introduction of its innovative NULISAqpcr™ AD 5-plex Assay. This groundbreaking product is poised to make significant contributions to Alzheimer's disease research by allowing the simultaneous quantitative assessment of five critical blood-based biomarkers. These biomarkers are integral to understanding Alzheimer’s disease as outlined by the Alzheimer's Association.

The NULISAqpcr™ AD 5-plex Assay offers measurement capabilities for:

• - Brain-derived phosphorylated tau 217 (BD-pTau217)
• - Neurofilament light chain (NfL)
• - Amyloid-beta 42 (Aβ42)
• - Glial fibrillary acidic protein (GFAP)
• - APOE4 carrier status

A New Era for Alzheimer's Research

The introduction of this assay signifies a major leap forward in neurodegenerative disease diagnostics. The assay condenses essential biomarkers into a single multiplexed format, which greatly enhances sensitivity and specificity. With the ability to assess BD-pTau217, Aβ42, NfL, and GFAP together, researchers can now effectively monitor amyloid and tau pathology, neurodegeneration, and inflammatory processes associated with Alzheimer's.

Additionally, the capability to accurately evaluate APOE4 carrier status, which stands as the most significant genetic risk factor for Alzheimer’s, is game-changing. This allows for better risk stratification and personalized approaches in both clinical and experimental settings. Not just limited to Alzheimer's, the assay may provide insights into various neurodegenerative conditions, further widening its impact.

Enhanced Accessibility and Cost-effectiveness

Dr. Steven Williams, chief scientific officer at Alamar, emphasized the importance of blood-based biomarkers in the quest for early diagnosis of Alzheimer’s. He stated, "Blood-based biomarkers are redefining Alzheimer's research, providing an accurate, cheaper and more accessible means of establishing early diagnosis and aiding determination of eligibility for therapies." Traditional single-plex assays would require multiple tests to attain a holistic view of the disease. The NULISA™ technology negates this by measuring multiple proteins simultaneously, giving a comprehensive insight into the underlying pathophysiology of Alzheimer's disease in a cost-effective manner.

Commitment to Collaborative Research

Alamar is committed to collaborating with researchers, healthcare professionals, and industry stakeholders to unlock the potential of precision proteomics. By providing effective tools such as the NULISAqpcr AD 5-plex Assay, Alamar aims to improve outcomes for those affected by Alzheimer's and other neurodegenerative disorders. This assay is now available through their Technology Access Program, further broadening access to researchers.

Conclusion

The NULISAqpcr AD 5-plex Assay by Alamar Biosciences is not only an innovative solution for Alzheimer's research but also has implications for a wider variety of neurodegenerative diseases. As the industry shifts towards blood-based biomarkers, this advancement may allow for more efficient detection, making a profound difference in patient care.

For more detailed information regarding this innovative assay and Alamar’s comprehensive portfolio of precision proteomic solutions, visit www.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately-owned life sciences firm focused on enhancing the early detection of diseases through precision proteomics. By leveraging their unique NULISA™ technology and the ARGO™ HT System, they aim to deliver ultra-high sensitivity that addresses notable limitations in existing technology, thereby revolutionizing proteomics.